Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors / Riesgo de COVID-19 grave en pacientes hipertensos tratados con inhibidores del sistema renina-angiotensina-aldosterona
Med. clín (Ed. impr.)
; 155(11): 488-490, dic. 2020. tab
Artigo
em Inglês
| IBECS
| ID: ibc-190829
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
INTRODUCTION:
There is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some authors suggested that blocking the renin-angiotensin system might actually decrease this risk.METHODS:
Retrospective cohort study of all the consecutive hypertensive patients with confirmed SARS-CoV-2 infection in a health area. The outcome variable was hospitalization because of severe Covid-19.RESULTS:
539 subjects were diagnosed of SARS-CoV-2 infection. Of these, 157 (29.1%) had hypertension and were included in the study. Sixty-nine cases (43.9%) were hospitalized because of severe Covid-19. In multivariable analysis older age, diabetes and hypertensive myocadiopathy were related to a higher risk of hospital admission. ARB treatment was associated with a significantly lower risk of hospitalization (HR 0.29, 95% CI 0.10 - 0.88). A similar albeit not significant trend was observed for ACEI.CONCLUSION:
ARB or ACEI treatment was not associated with a worse clinical outcome in consecutive hypertensive patients infected by SARS-CoV-2RESUMEN
INTRODUCCIÓN:
Existe controversia respecto al uso de los inhibidores de la enzima convertidora de angiotensina (IECA) o los bloqueadores de los receptores tipo I de la angiotensina II (ARA-II) para el tratamiento de la hipertensión arterial en COVID-19. Se ha sugerido que estos fármacos podrían tanto aumentar como reducir el riesgo de COVID-19 grave. PACIENTES YMÉTODO:
Estudio de cohortes retrospectivo de pacientes consecutivos de un área sanitaria, con hipertensión e infección por SARS-CoV-2. Variable deresultados:
ingreso hospitalario por COVID-19 grave.RESULTADOS:
Fueron diagnosticados 539 sujetos por infección por SARS-CoV-2. De estos, 157 (29,1%) eran hipertensos y se incluyeron en el estudio. Se ingresaron 69 (43,9%) pacientes por COVID-19 grave. En el análisis multivariante, la edad más elevada, la diabetes y la miocardiopatía hipertensiva se relacionaron con el riesgo de ingreso hospitalario. El tratamiento con ARA-II se asoció con un riesgo significativamente más bajo de ingreso (HR 0,29, IC 95% 0,10-0,88). Una tendencia similar, aunque no significativa, se encontró para los IECA.CONCLUSIÓN:
el tratamiento con ARA-II o IECA no se asoció con una peor evolución clínica en pacientes hipertensos consecutivos infectados por SARS-CoV-2
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Pneumonia Viral
/
Inibidores da Enzima Conversora de Angiotensina
/
Estudos de Coortes
/
Infecções por Coronavirus
/
Pandemias
/
Hipertensão
Limite:
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Med. clín (Ed. impr.)
Ano de publicação:
2020
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Universitario Lucus Augusti/Spain